Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat this disease. Selective BRAFV600E inhibitors, such as vemurafenib, typically induce initial, profound tumor regressions within this group of patients; however, durable responses have been hampered by the emergence of drug resistance. Here, we examined the activity of ganetespib, a small-molecule inhibitor of Hsp90, in melanoma lines harboring the BRAFV600E mutation. Ganetespib exposure resulted in the loss of mutant BRAF expression and depletion of mitogen-activated protein kinase and AKT signaling, resulting in greater in vitro potency and antitumor efficacy compared with targeted BRAF and MAP–ERK kinase (MEK) inhibitors. Dual targeting of Hsp90 and BRAFV600E provided combinatorial benefit in vemurafenib-sensitive melanoma cells in vitro and in vivo. Importantly, ganetespib overcame mechanisms of intrinsic and acquired resistance to vemurafenib, the latter of which was characterized by reactivation of extracellular signal-regulated kinase (ERK) signaling. Continued suppression of BRAFV600E by vemurafenib potentiated sensitivity to MEK inhibitors after acquired resistance had been established. Ganetespib treatment reduced, but not abolished, elevations in steady-state ERK activity. Profiling studies revealed that the addition of a MEK inhibitor could completely abrogate ERK reactivation in the resistant phenotype, with ganetespib displaying superior combinatorial activity over vemurafenib. Moreover, ganetespib plus the MEK inhibitor TAK-733 induced tumor regressions in vemurafenib-resistant xenografts. Overall these data highlight the potential of ganetespib as a single-agent or combination treatment in BRAFV600E-driven melanoma, particularly as a strategy to overcome acquired resistance to selective BRAF inhibitors. Mol Cancer Ther; 13(2); 353–63. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“The nature of the interactions was evaluated using the combination index method (18) and values generated using Median Effect analysis (Calcusyn Software; Biosoft).”
MethodCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502 · cited 1×
“facilitating aberrant cell survival and oncogene addiction (11, 12).”
BackgroundHSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496 · cited 3×
“The high frequency of these genetic modifications underscores a critical role for BRAF mutation in melanoma oncogenesis (1), as well as providing an actionable target for molecular therapeutic approaches in this disease.”
BackgroundInfluentialEpidemiology of invasive cutaneous melanoma
MacKie, R. M., Hauschild, A., & Eggermont, A. M. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp252 · Cited by 405 · cited 1×
“rates for many cancer types are showing encouraging declines (2), the worldwide incidence of melanoma continues to increase (3).”
BackgroundCorcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605714 · Cited by 314 · cited 1×
“the efficacy over single-agent treatments alone (29), but may also be an effective approach to prevent or delay the onset of resistance due to ERK reactivation (30, 31).”
Background
Cited by
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Mbofung, R. M., McKenzie, J. A., Malu, S., Zhang, M., Peng, W., Liu, C., Kuiatse, I., Tieu, T., Williams, L., Devi, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00449-z · Cited by 159
Self-citationGanetespib: research and clinical development
Modi, S., & Jhaveri, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s65804 · Cited by 92
“52 HSP90 inhibitors can also enhance tumor cell sensitivity to radiation.”
Sun, Q., Novak, D., Hüser, L., Poelchen, J., Wu, H., Granados, K., Federico, A., Liu, K., Steinfass, T., Vierthaler, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33591 · Cited by 20
Metadata
- Authors
- Acquaviva, J., Smith, D. L., Jimenez, J.-P., Zhang, C., Sequeira, M., He, S., Sang, J., Bates, R. C., & Proia, D. A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2014-02-01
- Volume
- 13
- Issue
- 2
- Pages
- 353-363
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2100370559
- Cited by
- 101
- References
- 10
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0481
- The paper
- Acquaviva, J., Smith, D. L., Jimenez, J.-P., Zhang, C., Sequeira, M., He, S., Sang, J., Bates, R. C., & Proia, D. A. (2014). Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.